Corporate Summary

Stock Quote
MNTA (Common Stock)
ExchangeNASDAQ (US Dollar)
Change (%) Stock is Down 0.03 (0.30%)
Data as of 09/10/07 10:05 a.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore >>
There are currently no news releases.
Upcoming EventsMore >>
There are currently no events scheduled.
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Momenta Pharmaceuticals, Inc. posts new information to the site. Just enter your e-mail address and click Submit.

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Forward-Looking Statements
This web site contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements about our future expectations, plans, prospects, operating results, discovery and development of products and intellectual property, are made as of the date they were first issued and were based on current expectations, estimates, forecasts and projections as well as the beliefs and assumptions of our management. Words such as “expect,” “anticipate,” “should,” “believe,” “hope,” “target,” “project,” “goals,” “estimate,” “potential,” “predict,” “may,” “will,” “might,” “could,” “would,” “intend,” “will enable,” “would be expected,” “look forward,” “may provide,” “could increase the likelihood” or similar terms, variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond our control, including, among others: our ability to obtain approval for and commercialize our most advanced product candidate, M-Enoxaparin; the outcome of potential patent litigation with Sanofi-Aventis, the innovator of Lovenox; the approval and successful commercialization of generic versions of Lovenox; the success of our preclinical studies and clinical trials for our development candidates, including M118; the failure of Sandoz to adequately perform under either of our collaborations with Sandoz, or we or Sandoz terminate all or a portion of either collaboration; our ability to obtain and enforce patent protection for our discoveries; and the other factors described under the heading “Risk Factors” in the most recent annual or quarterly report that we have filed with the Securities and Exchange Commission. As a result of such risks, uncertainties and factors, our actual results may differ materially from any future results, performance or achievements discussed in or implied by any forward-looking statements. Past performance is not necessarily indicative of future results. This web site and the information contained herein do not constitute an offer or solicitation of an offer for sale of any securities, and none of the information contained herein is intended to be and shall not be deemed to be, incorporated into any of our securities filings or documents. We undertake no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.